Pharmacogenetics and Schizophrenia

Adriana Elena Foster, Del D. Miller, Peter F Buckley

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Emergent pharmacogenetic studies indicate that the efficacy of antipsychotic medications in schizophrenia may be predicted through genetic analysis. There also is evidence that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain, glucose and lipid abnormalities, and tardive dyskinesia may be predicted by pharmacogenetic analysis in this patient population. In the future, this targeted approach with the choice of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic status may gain hold as new treatments are developed with even fewer side effects.

Original languageEnglish (US)
Pages (from-to)417-435
Number of pages19
JournalPsychiatric Clinics of North America
Volume30
Issue number3
DOIs
StatePublished - Sep 1 2007

Fingerprint

Pharmacogenetics
Antipsychotic Agents
Schizophrenia
Weight Gain
Lipids
Glucose
Population
Pharmacogenomic Testing
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Foster, A. E., Miller, D. D., & Buckley, P. F. (2007). Pharmacogenetics and Schizophrenia. Psychiatric Clinics of North America, 30(3), 417-435. https://doi.org/10.1016/j.psc.2007.04.004

Pharmacogenetics and Schizophrenia. / Foster, Adriana Elena; Miller, Del D.; Buckley, Peter F.

In: Psychiatric Clinics of North America, Vol. 30, No. 3, 01.09.2007, p. 417-435.

Research output: Contribution to journalReview article

Foster, AE, Miller, DD & Buckley, PF 2007, 'Pharmacogenetics and Schizophrenia', Psychiatric Clinics of North America, vol. 30, no. 3, pp. 417-435. https://doi.org/10.1016/j.psc.2007.04.004
Foster, Adriana Elena ; Miller, Del D. ; Buckley, Peter F. / Pharmacogenetics and Schizophrenia. In: Psychiatric Clinics of North America. 2007 ; Vol. 30, No. 3. pp. 417-435.
@article{4d1a4a0e1c7549b7a629c708123e6689,
title = "Pharmacogenetics and Schizophrenia",
abstract = "Emergent pharmacogenetic studies indicate that the efficacy of antipsychotic medications in schizophrenia may be predicted through genetic analysis. There also is evidence that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain, glucose and lipid abnormalities, and tardive dyskinesia may be predicted by pharmacogenetic analysis in this patient population. In the future, this targeted approach with the choice of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic status may gain hold as new treatments are developed with even fewer side effects.",
author = "Foster, {Adriana Elena} and Miller, {Del D.} and Buckley, {Peter F}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.psc.2007.04.004",
language = "English (US)",
volume = "30",
pages = "417--435",
journal = "Psychiatric Clinics of North America",
issn = "0193-953X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics and Schizophrenia

AU - Foster, Adriana Elena

AU - Miller, Del D.

AU - Buckley, Peter F

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Emergent pharmacogenetic studies indicate that the efficacy of antipsychotic medications in schizophrenia may be predicted through genetic analysis. There also is evidence that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain, glucose and lipid abnormalities, and tardive dyskinesia may be predicted by pharmacogenetic analysis in this patient population. In the future, this targeted approach with the choice of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic status may gain hold as new treatments are developed with even fewer side effects.

AB - Emergent pharmacogenetic studies indicate that the efficacy of antipsychotic medications in schizophrenia may be predicted through genetic analysis. There also is evidence that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain, glucose and lipid abnormalities, and tardive dyskinesia may be predicted by pharmacogenetic analysis in this patient population. In the future, this targeted approach with the choice of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic status may gain hold as new treatments are developed with even fewer side effects.

UR - http://www.scopus.com/inward/record.url?scp=34548087223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548087223&partnerID=8YFLogxK

U2 - 10.1016/j.psc.2007.04.004

DO - 10.1016/j.psc.2007.04.004

M3 - Review article

VL - 30

SP - 417

EP - 435

JO - Psychiatric Clinics of North America

JF - Psychiatric Clinics of North America

SN - 0193-953X

IS - 3

ER -